Obinutuzumab (Gazyva) — CPB 0877 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0877 governing obinutuzumab (Gazyva) coverage policy, effective November 1, 2025. Here's what billing teams need to know before submitting claims under J9301.

Aetna updated CPB 0877 to expand the approved indications for obinutuzumab (Gazyva), billing primarily under HCPCS J9301 (injection, obinutuzumab, 10 mg) with infusion administration reported via CPT 96413 and +96415. The policy now covers CLL/SLL, follicular lymphoma, multiple marginal zone lymphoma subtypes, and several other B-cell malignancies under specific combination regimen requirements. If your oncology or hematology practice bills Aetna commercial plans for obinutuzumab, this coverage policy update directly affects your prior authorization submissions and claim documentation starting November 1, 2025.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Obinutuzumab (Gazyva) — CPB 0877
Policy Code	CPB 0877
Change Type	Modified
Effective Date	November 1, 2025
Impact Level	High
Specialties Affected	Hematology, Medical Oncology, Infusion Centers, Hospital Outpatient
Key Action	Audit prior authorization submissions to confirm the requested regimen matches an approved combination listed in CPB 0877 before billing J9301

---

Aetna Obinutuzumab Coverage Criteria and Medical Necessity Requirements 2025

The Aetna obinutuzumab coverage policy under CPB 0877 is indication-specific and regimen-specific. "Medically necessary" here does not mean the drug is appropriate for any B-cell malignancy — it means the drug must be used in an exact combination or context that Aetna has approved. Getting that wrong on a prior authorization request is the fastest path to a claim denial.

Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)

Aetna covers obinutuzumab for CLL/SLL in two scenarios. First, as a single agent or in combination with acalabrutinib, venetoclax, acalabrutinib plus venetoclax, bendamustine (J9033, J9034, J9056, J9058, J9059), or chlorambucil (S0172). Second, in combination with high-dose methylprednisolone (J1010 or J2919) for CLL/SLL with del(17p)/TP53 mutation — this applies to both first-line treatment and relapsed/refractory disease.

That del(17p)/TP53 carve-out matters. You need the mutation documented in the chart and reflected in your ICD-10 coding before prior auth submission.

Follicular Lymphoma (FL)

Aetna covers obinutuzumab for follicular lymphoma up to 30 months total. That treatment duration cap is the most operationally significant detail in this section. Your billing team and prior auth team need to track cumulative treatment time, not just individual authorization periods.

Approved first-line combinations include CHOP (cyclophosphamide at J8530/J9070–J9076, doxorubicin at J9000, vincristine at J9370/J9371, prednisone at J7512), CVP, and bendamustine. For subsequent therapy, the policy also allows single-agent obinutuzumab, combinations with lenalidomide, bendamustine, CHOP, or CVP. Maintenance therapy as a single agent is covered. One addition stands out: obinutuzumab in combination with zanubrutinib (Brukinsa) is now covered as third-line and subsequent therapy for follicular lymphoma.

Obinutuzumab is also covered as a rituximab substitute (J9312 would be the rituximab code, but here it's replaced) when a member has documented intolerance or rare complications — specifically mucocutaneous reactions including paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, or toxic epidermal necrolysis. Document those reactions explicitly in the prior auth. "Rituximab intolerance" alone will not be enough.

Marginal Zone Lymphomas

Aetna covers obinutuzumab for three marginal zone subtypes, each with distinct criteria.

Extranodal and Splenic Marginal Zone Lymphoma: Covered as subsequent therapy in combination with bendamustine or lenalidomide, as maintenance therapy after prior treatment with obinutuzumab plus bendamustine, and as a rituximab substitute with documented intolerance.

Nodal Marginal Zone Lymphoma: Covered as first-line therapy with CHOP, CVP, or bendamustine. Covered as subsequent therapy with bendamustine or lenalidomide. Covered as maintenance after obinutuzumab plus bendamustine. Covered as rituximab substitute with documented intolerance.

The maintenance therapy coverage for marginal zone lymphomas hinges on prior treatment with obinutuzumab and bendamustine specifically. Prior treatment with obinutuzumab plus something else does not qualify.

Hepatitis B Screening Requirement

The ICD-10 codes included in CPB 0877 include hepatitis B diagnoses (B16.0–B16.9, B18.0, B18.1). This reflects the clinical requirement to screen for hepatitis B before starting obinutuzumab — not that hepatitis B is a covered treatment indication. If your practice is coding hepatitis B as a secondary diagnosis on claims for monitoring purposes, confirm your documentation supports that link.

---

Aetna Obinutuzumab Exclusions and Non-Covered Indications

The policy structure here is permissive-by-list — if an indication or combination is not explicitly listed, it is not covered. That's a different posture than some payers take, and it matters for obinutuzumab billing. Regimens not enumerated above are not covered under the medical necessity criteria, regardless of clinical rationale.

For follicular lymphoma specifically, the policy specifies a 30-month cumulative treatment duration limit. Claims for obinutuzumab beyond that window fall outside the stated coverage period in CPB 0877.

---

Coverage Indications at a Glance

Prior authorization requirements are not explicitly stated in CPB 0877 as provided. Verify Aetna's administrative requirements separately before submitting claims.

---

Aetna Obinutuzumab Billing Guidelines and Action Items 2025

The effective date for this modified policy is November 1, 2025. Any claims for obinutuzumab services on or after that date fall under these updated criteria. Here's what your team needs to do now.

Copy Action Items

If your patient mix includes a high volume of marginal zone lymphoma or follicular lymphoma patients, talk to your compliance officer before the November 1 effective date. The maintenance therapy criteria for marginal zone subtypes are narrow, and the regimen-specific requirements leave little room for documentation gaps.

---

CPT, HCPCS, and ICD-10 Codes for Obinutuzumab Under CPB 0877

Covered HCPCS Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
J9301	HCPCS	Injection, obinutuzumab, 10 mg

Supporting Drug Codes (Combination Regimen Components)

Note: J9286 (injection, glofitamab-gxbm, 2.5 mg) appears in CPB 0877 under the same supporting drug code group but applies to coverage criteria not fully addressed in this summary. Refer to the complete CPB 0877 policy to confirm the specific regimen context before billing J9286 alongside J9301.

CPT Administration Codes

Code	Type	Description Copy
96413	CPT	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance
+96415	CPT	Each additional hour (add-on code; list separately in addition to primary code)

Key ICD-10-CM Diagnosis Codes

CPB 0877 includes 278 ICD-10-CM codes in total. The table above reflects only codes confirmed in the available source data. Additional ICD-10-CM codes are included in the full policy. Refer to the complete policy source to confirm applicable codes for your patient population — only codes confirmed in the policy should be billed. Review the full list at the Aetna CPB 0877 policy source.

---